In its first year of use in the United States, the overall estimated effectiveness of the respiratory syncytial virus (RSV) vaccine against respiratory illness and severe disease in adults aged 60 years and older was 92%, a team led by…
AP The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors.
People with advanced lung or skin cancer…








